Compare SLDP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | URGN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.3M | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | SLDP | URGN |
|---|---|---|
| Price | $5.31 | $22.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.00 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 10.0M | 1.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $19,802,000.00 | ★ $96,516,000.00 |
| Revenue This Year | $27.38 | $27.96 |
| Revenue Next Year | $36.18 | $123.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.85 | 8.00 |
| 52 Week Low | $0.68 | $3.42 |
| 52 Week High | $8.86 | $30.00 |
| Indicator | SLDP | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 45.79 |
| Support Level | $4.78 | $24.00 |
| Resistance Level | $5.33 | $30.00 |
| Average True Range (ATR) | 0.37 | 1.76 |
| MACD | -0.04 | -0.54 |
| Stochastic Oscillator | 42.77 | 5.74 |
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.